Edition:
United Kingdom

Benitec Biopharma ‍Says U.S. FDA Granted Orphan Drug Designation To BB-301​


Sunday, 14 Jan 2018 

Jan 15 (Reuters) - Benitec Biopharma Ltd ::‍U.S. FDA HAS GRANTED ORPHAN DRUG DESIGNATION TO BB-301 FOR TREATMENT OF OCULOPHARYNGEAL MUSCULAR DYSTROPHY(OPMD)​. 

Company Quote

1.75
-0.06 -3.31%
18 Apr 2019